Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.
Surmodics, Inc. provides medical device and in vitro diagnostic technologies for the health care industry. Its company news has included clinical and regulatory disclosures for the Pounce™ Thrombectomy Platform, including PROWL Registry analyses of peripheral arterial thrombectomy in symptomatic lower-extremity limb ischemia.
Coverage has also included operating and financial results, material agreements, capital-structure updates, and the completed 2025 merger that converted Surmodics from a Nasdaq-listed public company into a wholly owned subsidiary. Product-related updates focus on FDA-cleared mechanical thrombectomy systems designed for non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.
Surmodics, Inc. (Nasdaq: SRDX) will host a live webcast of its Q1 fiscal 2021 conference call on February 9, at 7:30 a.m. CT. An earnings news release will precede the call. Key executives including CEO Gary Maharaj and CFO Tim Arens will discuss financial results and accomplishments. The webcast can be accessed via the investor relations section of the company’s website. An audio replay will be available from February 9 to February 16. Surmodics specializes in surface modification technologies for medical devices and aims to address unmet clinical needs.
Surmodics, Inc. (NASDAQ:SRDX) announced the presentation of 12-month data from its TRANSCEND clinical trial at the Leipzig Interventional Course 2021. This trial compared the efficacy and safety of the SurVeil™ drug-coated balloon (DCB) against the IN.PACT® Admiral® DCB in patients with femoropopliteal artery disease. Results showed that SurVeil DCB is non-inferior to the higher drug dose IN.PACT Admiral while using a substantially lower paclitaxel dose. The SurVeil DCB exhibited a primary patency rate of 81.7% and a strong safety profile, suggesting it may set a new standard in PAD treatment.
Surmodics, Inc. (NASDAQ:SRDX) has announced the presentation of 12-month data from its TRANSCEND clinical trial at the Leipzig Interventional Course (LINC) 2021 virtual event on January 25, 2021. Dr. Kenneth Rosenfield will present findings comparing the SurVeil drug-coated balloon with the IN.PACT Admiral drug-coated balloon for treating femoropopliteal artery disease. The trial evaluated the safety and efficacy of the SurVeil device, involving 446 patients across 65 sites, focusing on primary patency and safety endpoints.
Surmodics, Inc. (NASDAQ:SRDX) presented 6-month data from its AVESS first-in-human study of the Avess™ AV Fistula drug-coated balloon (DCB) at the Vascular Interventional Advances (VIVA) 2020 virtual conference. The study indicated a target lesion patency of 90.9% at 6 months and no reported adverse events. The Avess DCB, designed to minimize paclitaxel exposure, aims to enhance vascular treatment by improving drug distribution within arteries. Data was collected from 12 patients, emphasizing the device's safety and potential benefits in vascular access management.
Surmodics, Inc. (Nasdaq: SRDX) reported fourth quarter fiscal 2020 revenue of $22.5 million, down 27% year-over-year. The company experienced a GAAP loss per share of ($0.22), compared to earnings of $0.26 in the prior year. Medical Device revenue declined 31% to $17.2 million, influenced by $1.6 million from a deal with Abbott Vascular. In Vitro Diagnostics revenue was $5.4 million, a 10% decrease. Cash and short-term investments stood at $61.1 million with no debt. The company has refrained from providing future guidance due to COVID-19 uncertainties.
Surmodics, Inc. (Nasdaq: SRDX) will host a live webcast on November 4, 2020, at 4 p.m. CT to discuss its fourth quarter fiscal 2020 results. The earnings release will be issued post-market close that day. CEO Gary Maharaj and CFO Tim Arens will detail financial results and accomplishments during the call. An audio replay will be available from 7 p.m. CT on November 4 until 7 p.m. CT on November 11. Surmodics specializes in surface modification technologies for medical devices and chemical components for in vitro diagnostic tests.